DrugPatentWatch Database Preview

Details for Patent: 8,420,056

« Back to Dashboard

Which drugs does patent 8,420,056 protect, and when does it expire?

Patent 8,420,056 protects NUCYNTA ER and is included in one NDA.

This patent has one hundred and seventy-seven patent family members in thirty-one countries.

Summary for Patent: 8,420,056

Title:	Abuse-proofed dosage form
Abstract:	The invention relates to a dosage form that is thermoshaped without being extruded and that is safeguarded from abuse, comprising at least one synthetic or natural polymer having a breaking strength of at least 500 N in addition to one or more active substances that could be subject to abuse and optionally physiologically acceptable adjuvants. The invention also relates to a corresponding method for producing said dosage form.
Inventor(s):	Arkenau-Maric; Elisabeth (Koln, DE), Bartholomaus; Johannes (Aachen, DE), Kugelmann; Heinrich (Aachen, DE)
Assignee:	Grunenthal GmbH (Aachen, DE)
Application Number:	13/270,505
Patent Claim Types: see list of patent claims	Compound; Dosage form; Process; Composition;

Drugs Protected by US Patent 8,420,056

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Collegium Pharm Inc	NUCYNTA ER	tapentadol hydrochloride	TABLET, EXTENDED RELEASE;ORAL	200533-001	Aug 25, 2011		RX	Yes	No			Y
Collegium Pharm Inc	NUCYNTA ER	tapentadol hydrochloride	TABLET, EXTENDED RELEASE;ORAL	200533-002	Aug 25, 2011		RX	Yes	No			Y
Collegium Pharm Inc	NUCYNTA ER	tapentadol hydrochloride	TABLET, EXTENDED RELEASE;ORAL	200533-003	Aug 25, 2011		RX	Yes	No			Y

International Family Members for US Patent 8,420,056

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	045352
Argentina	045353
Argentina	046994